Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Alnylam Pharmaceuticals
So what: Roche Holding AG announced it would end its partnership with Tekmira Pharmaceuticals, dragging Alnylam down in the fray. This move affects research for RNAi therapeutics, a focus for Alnylam.
Now what: In a release today, Alnylam expressed disappointment that Roche was no longer supporting RNAi therapeutics research, but this isn't the end of the world. Alnylam will continue its research, and management believes "we are on the frontier of demonstrating human proof-of-concept for these and other programs." If you're looking for an opportunity to get into Alnylam, today is as good as any.
Interested in more info on Alnylam? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings, or follow his Motley Fool CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
There's a lot of good news potentially on the way for the biotech. But its 2017 performance will be hard to beat.
This Is Why Alnylam Pharmaceuticals Soared 249% in 2017
It was a breakout year for the clinical-stage biotech.
Alnylam Gets Some Welcome News
A trial that had been on clinical hold because of a patient death has been cleared to restart.